Pashtoon Kasi MD, MS
@pashtoonkasi
Oncologist |Researcher| ColorectalCancer #CRCSM👨🏼🎓@MayoClinic @PittTweet Alum 🧬#ctDNA #LiquidBiopsies #PrecisionOncology @CityOfHope Views my own-COI @ASCO
🆕🗞️Just out 🪺#NEST-1 trial results👇🏾 Are we on the verge of a new drug combo for colon or rectal cancer? Substantial & brisk responses to just☝🏾dose of BOT🟢➕BAL🔹🔹 immunotherapy.🙌🏾 Pattern & kill is unprecedented🌊. @ASCO #GI24 @OncoAlert Abstract 117📍Poster Board H2
Thank you - let me know if any questions/things I can help with!!
Congrats @NiuSanford on @NRGOncology GI-011 activated! Tagging my #GI colleagues in #LosAngeles to support enrollment. @DaniCastilloMD @gagan_brar24 @mgfakih @DrElkhoueiry @DrJZell @pashtoonkasi
Excited to be at my first @NRGonc meeting & even more excited about the recently opened trials presented in the general #radonc ☢️ meeting! 🤗 Can’t wait to learn more in the upcoming session! @AnnKloppMD @NiuSanford
Kudos 👏🏽 to @COH_SurgOnc team on the 📝 Supports @OHSUKnight findings of the benefits of reduced #HAI⛽️ dose in unresectable CRLM from #IsaacSchwantes and @drymtn link.springer.com/article/10.124…
🆕article📰showing the value of the LIVER PUMP⏺️ Hepatic arterial infusion (HAI) therapy for patients with resected colorectal cancer liver metastases (CRLM). 💡Reduced dosing leads to⬇️toxicity with preserved survival benefits. @OncoAlert #CRCSM link.springer.com/article/10.124…
Congrats to Dr Labadie, future Dr Fan and the rest of the @cityofhope team for getting this out. Preserved survival with lower doses 🟰 less toxicity for patients!
🆕article📰showing the value of the LIVER PUMP⏺️ Hepatic arterial infusion (HAI) therapy for patients with resected colorectal cancer liver metastases (CRLM). 💡Reduced dosing leads to⬇️toxicity with preserved survival benefits. @OncoAlert #CRCSM link.springer.com/article/10.124…
Beeindruckend: Gleiche Überlebensraten mit weniger Toxizität – genau der Fortschritt, den wir in der Onkologie brauchen! #CRCSM
Our new cancer specialty hospital — opening in 2025 — was built for one purpose: saving lives. 💙 It brings leading-edge research, complex surgeries, clinical trials & supportive care closer to home. Learn more: bit.ly/4nM20v3
Our #liquidbiopsies #ctDNA paper now @Nature_NPJ @Nature @nresearchnews. #Cholangiocarcinoma #hpbcsm #bileductcancer ➡️Target Rich but often lack of a good tissue biopsy (ERCP/EUS) to do genomic testing. #PrecisionMedicine #IndividualizedMedicine #Cancer nature.com/articles/s4169…
🆕🗞️Published today @JCOPO_ASCO @ASCO The1️⃣st AGNOSTIC study of a PARP⛔️inhibitor: 📚LODESTAR: Rucaparib💊 🎯Need to think about variants in Homologous Recombination Repair (HRR) Genes 🧬 beyond canonical #BRCA #PALB2. 💡Novel insights. @OncoAlert 🔗ascopubs.org/doi/10.1200/PO…

When gratitude hits the road. 🚚💙 We love to see grateful patient Mario Gonzalez's heartfelt and public message: 'Thank you, City of Hope.' Mario, your words mean everything to us. Thank you for trusting us with your care. 💙 #ThisisHope #CityofHopeOC
The 1st Agnostic Study of a PARP Inhibitor - @pashtoonkasi oncodaily.com/insight/pashto… #Cancer #OncoDaily #Medicine #Oncology #MedEd #MedX #MedNews @CancerWorldmag
🟣 Most active cancer institutes on X in Q2 2025, based on oncologists' posts and views. Explore more about oncology conferences, top trials, and reactions from oncologists: clin.larvol.com #LARVOL #Oncology #CancerResearch #ClinicalTrials #OncologyInsights #CancerData…
LODESTAR: A Single-Arm Phase II Study of Rucaparib in Solid Tumors With Pathogenic Germline or Somatic Variants in Homologous Recombination Repair Genes [Jul 9, 2025] Anbil et al. @JCOPO_ASCO ascopubs.org/doi/10.1200/PO… #PrecisionMedicine
Top #GICancer Oncologists for Q2 2025, curated by @Larvol CLIN. Explore more about oncology conferences, top trials, and reactions from oncologists: clin.larvol.com #LARVOL #Oncology #CancerResearch #CancerData #OncologyInsights | @Erman_Akkus | @ArndtVogel |…
Adding: 🧬ERRFI1 (ERBB Receptor Feedback Inhibitor 1) - maybe pronounced as ERR-FY-1️⃣ 🧬RET fusions earlier with @VivekSubbiah #ASCO20 data. #HPBCSM #Cholangiocarcinoma #curecc
“You are what you eat,” as they say. 🎙️Here’s the link to the interview and insights with @BusinessInsider 🗞️ 📰. @Hilarx ✍️ What we put on our plate matters more than ever. 💡Complex interplay of diet and microbiome. 🔗 businessinsider.com/colon-cancer-d…